Insights from 2023 ASH Annual Meeting


 

ASH 2023 Insights: "Oral Decitabine/Cedazuridine (ASTX727) & Venetoclax in Combination With IDH1 or IDH2 Inhibitor Therapy for IDHmut AML"

28 views
December 20, 2023
Comments 0
Login to view comments. Click here to Login